AI is spitting out more potential drugs than ever. This start-up wants to figure out which ones matter.

10x Science, a biotech startup founded in December 2025, raised $4.8M in seed funding to address a bottleneck in AI-driven drug discovery: while AI can generate drug candidates at scale, characterizing and validating them remains labor-intensive. Founded by biochemists David Roberts and Andrew Reiter alongside serial founder Vishnu Tejas, the startup aims to automate the measurement and structural analysis phase that precedes drug testing and production.